Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Buy" from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received a consensus rating of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $23.33.

IMNM has been the subject of a number of research analyst reports. Wedbush reissued an "outperform" rating and set a $21.00 target price (down previously from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. Lake Street Capital initiated coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 target price for the company. Finally, Stephens reissued an "overweight" rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th.

Insider Buying and Selling at Immunome

In related news, Director Jean Jacques Bienaime bought 5,000 shares of Immunome stock in a transaction that occurred on Tuesday, June 3rd. The stock was acquired at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the purchase, the director owned 36,415 shares in the company, valued at approximately $341,572.70. This represents a 15.92% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC lifted its stake in Immunome by 3.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company's stock worth $470,000 after purchasing an additional 1,643 shares during the period. Voya Investment Management LLC lifted its stake in Immunome by 21.2% during the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company's stock worth $127,000 after purchasing an additional 3,305 shares during the period. Rhumbline Advisers lifted its stake in Immunome by 30.4% during the first quarter. Rhumbline Advisers now owns 88,888 shares of the company's stock worth $598,000 after purchasing an additional 20,721 shares during the period. Woodline Partners LP lifted its stake in Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock worth $11,157,000 after purchasing an additional 676,804 shares during the period. Finally, Zimmer Partners LP bought a new position in Immunome during the first quarter worth about $673,000. Institutional investors own 44.58% of the company's stock.

Immunome Price Performance

NASDAQ:IMNM traded down $0.11 during trading hours on Monday, reaching $8.40. The company's stock had a trading volume of 984,556 shares, compared to its average volume of 902,919. The company has a market cap of $730.88 million, a price-to-earnings ratio of -2.64 and a beta of 1.92. Immunome has a one year low of $5.15 and a one year high of $16.81. The business's 50-day moving average is $8.66 and its 200-day moving average is $8.90.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The firm had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. On average, sell-side analysts predict that Immunome will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.